Curcumin Supplement in Nonalcoholic Fatty Liver Patients

The Effect of Curcumin Supplement on Metabolic Factors and Hepatic Fibrosis in Nonalcoholic Fatty Liver Patients

Status

Completed

Phases

Phase 2Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02908152

Enrollment

Registered

2016-09-20

Start date

2017-02-10

Completion date

2017-10-10

Last updated

2020-09-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nonalcoholic Fatty Liver, Type 2 Diabetes

Brief summary

The purpose of this study is to investigate the effects of curcumin supplement on metabolic factors and hepatic fibrosis in nonalcoholic fatty liver patients with type 2 diabetes. Subjects will participate in 3 month, two group, randomized intervention, where one group (n=25) will take 1.5g/d curcumin and the other group (n=25) will take a placebo to compare differences in outcomes between the two groups.

Interventions

DIETARY_SUPPLEMENTcurcumin

1500 mg 1 capsule / day for 12 weeks

DIETARY_SUPPLEMENTplacebo

1500 mg 1 capsule / day for 12 weeks

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

30 Years to 65 Years

Healthy volunteers

Inclusion criteria

* Patient diagnosed with type 2 diabetes based on ADA definition or who only take oral antidiabetic drug; * CAP score \>263.

Exclusion criteria

* Taking any kind of antibiotics two weeks before recruitment; * History of alcohol consumption; * pregnancy or lactation; * Professional athletes; * Other liver disease (viral/etc); * High dose synthetic estrogens, methotrexate, amiodarone, steroids, chloroquine, immunosuppressive drugs; * A history of Cardiovascular disease; * Renal disease, Celiac disease, Cirrhosis; * History of Upper GI surgery; * A history of hypothyroidism or Cushing's syndrome; * History of drug dependence; * Body mass index (BMI) ≥35 kg/m2; * A restrictive diet or weight change ≥ 5 kg during the 3months prior to study; * Any change in treatment with oral hypoglycemic; anti hypertensive and antilipid agents during the study; * Use of weight loss medications.

Design outcomes

Primary

Measure	Time frame	Description
Hepatic steatosis	[12 weeks]	measured by CAP score using Fibroscan

Secondary

Measure	Time frame
Glucose	[12 weeks]
HBA1C	[12 weeks]
ALT	[12 weeks]
AST	[12 weeks]

Countries

Iran

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 2, 2026